Quinupramine is a tricyclic antidepressant (TCA) with a unique chemical structure. It is chemically similar to imipramine, but with a different side chain. Its synthesis involves a multi-step process starting with the reaction of 3-chloro-4-fluoroaniline with 1-(2-chloroethyl)-4-piperidinol. Quinupramine has a potent anticholinergic effect and is considered a strong serotonin reuptake inhibitor. However, it has a relatively short half-life and is not widely used in clinical practice. Research suggests that quinupramine may have therapeutic potential for the treatment of anxiety disorders and other conditions, but more studies are needed to confirm its efficacy and safety. Its unique pharmacological properties make it an interesting target for further research, especially in exploring its potential as a drug for disorders related to serotonin neurotransmission.'
quinupramine: RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 93154 |
| CHEMBL ID | 107360 |
| CHEBI ID | 135292 |
| SCHEMBL ID | 49100 |
| MeSH ID | M0091320 |
| Synonym |
|---|
| kevopril |
| quinupramine |
| D07336 |
| quinupramine (inn) |
| 31721-17-2 |
| OPREA1_740272 |
| CHEBI:135292 |
| CHEMBL107360 |
| 11-(1-azabicyclo[2.2.2]octan-3-yl)-5,6-dihydrobenzo[b][1]benzazepine |
| 5-(3-chinuclidinyl)-10,11-dihydro-5h-dibenz(b,f)azepin |
| quinupramina [inn-spanish] |
| 5h-dibenz(b,f)azepine, 10,11-dihydro-5-(3-quinuclidinyl)- |
| 10,11-dihydro-5-(3-quinuclidinyl)-5h-dibenz(b,f)azepine |
| einecs 250-780-3 |
| quinupramina |
| quinupraminum |
| quinupraminum [inn-latin] |
| quinupramine [inn:dcf] |
| 29o61hff4l , |
| unii-29o61hff4l |
| FT-0674293 |
| quinupramine [inn] |
| quinupramine [who-dd] |
| quinupramine [mi] |
| quinupramine [mart.] |
| SCHEMBL49100 |
| DB13246 |
| Q7272541 |
| kevopril; kinupril; lm 208 |
| CS-0026094 |
| HY-106578 |
| DTXSID70865608 |
| EN300-18563724 |
| 2-{1-azabicyclo[2.2.2]octan-3-yl}-2-azatricyclo[9.4.0.0,3,8]pentadeca-1(11),3(8),4,6,12,14-hexaene |
Quinupramine is a novel and original antidepressant due to its selective and specific affinity for central muscarinic receptors and the lack of subsequent metabolites.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Quinupramine is a novel and original antidepressant due to its selective and specific affinity for central muscarinic receptors and the lack of subsequent metabolites. " | ( [New antidepressant multicenter study in hospitalized patients: quinupramine (author's transl)]. Chevalier, JF; Deniker, P; Garreau, G; Loo, H, 1982) | 1.95 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " Pharmacokinetic studies on quinupramine and imipramine in plasma and brain were also performed in rats after a single oral administration." | ( Effects of quinupramine on the central monoamine uptake systems and involvement of pharmacokinetics in its pharmacological activities. Kohno, S; Murai, K; Nishimoto, T; Ohata, K; Sakamoto, H; Tatsumi, H; Yokoyama, N, 1987) | 0.96 |
| "The pharmacokinetic study of quinupramin was developed on healthy volunteers, after cross-over administrations of three doses (2." | ( [Crossover pharmacokinetic study of quinupramine in 6 subjects]. Bouquet, S; Fourtillan, JB; Girault, J; Lefebvre, MA, 1982) | 0.54 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " The calculated kinetic data for Quinupramin indicated a good bioavailability for the oral doses (2." | ( [Crossover pharmacokinetic study of quinupramine in 6 subjects]. Bouquet, S; Fourtillan, JB; Girault, J; Lefebvre, MA, 1982) | 0.54 |
| " The pharmacokinetics and bioavailability of quinupramine from an EVA matrix were examined to determine the level of percutaneous absorption in rats." | ( Development and biopharmaceutical evaluation of quinupramine-EVA matrix containing penetration enhancer for the enhanced transdermal absorption in rats. Cho, CW; Kim, J; Kim, SJ; Kim, WJ; Shin, SC, 2007) | 0.85 |
| Class | Description |
|---|---|
| dibenzooxazepine | An organic heterotricyclic compound consisting of two benzene rings fused to a seven-membered ring containing one oxygen and one nitrogen atom. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 12 (75.00) | 18.7374 |
| 1990's | 1 (6.25) | 18.2507 |
| 2000's | 3 (18.75) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (20.90) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 2 (12.50%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 14 (87.50%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||